Clinically, estrogen receptor (ER), along with progesterone receptor (PgR) and human epidermal growth factor receptor 2 (Her2) expression status are essential molecular markers for the assessment of adjuvant treatment options and prognosis for breast cancer patients. Here, ESR1 is linked to breast carcinoma.